Objective. To report the long-term outcome of neurologic involvement in patients with Behçet's disease (BD).Methods. We performed a retrospective analysis of 115 patients who fulfilled the international criteria for BD (57% male; median age 37 years [interquartile range (IQR) 30-46 years]) and had neuro-BD (NBD) after exclusion of cerebral venous thrombosis. Factors associated with relapse of NBD, inability to perform activities of daily living, and mortality were assessed.Results. Seventy-eight patients (68%) presented with acute NBD and 37 (32%) presented with a progressive course. The HLA-B51 allele was carried by 49% of the patients. Overall, 46 of 115 patients (40%) had severe disability at baseline, represented by a Rankin score of >3. The 5-and 7-year event-free survival rates were 65% and 53%, respectively. In multivariate analysis, a positive HLA-B51 status was independently associated with the risk of NBD relapse, with an odds ratio (OR) of 3.6 (95% confidence interval [95% CI] 1.5-9.1). Conclusion. Our findings indicate that NBD is a severe condition in which patients with the HLA-B51 allele appear to experience a worse prognosis. After a median followup of 73 months (IQR

No abstract

Background and Purpose: Cangrelor is a P2Y12 inhibitor that presents the advantage of having a short half-life. Its use may be helpful in the management of antiplatelet therapy for patients treated with stent assisted coiling or flow-diverter stents. The purpose of our study was to report our early experience in using cangrelor for such indications.